Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for PTSD With or Without Psychotherapy
NCT06407635Phase 1Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Jun 2024
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of psilocybin in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Incidence of Adverse Events at 8 months, Columbia Suicide Severity Rating Scale at 8 months and 3 more. Started Jun 2024; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06407635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06407635.